This meeting is supported by:
PROGRAMME
| 09.00 - 09.30 | Arrival, registration and coffee |
| 09.30 - 09.40 | Welcome and introduction Pam Brown, Pam Brown Consulting |
|
Session 1 Chair: Pam Brown, Pam Brown Consulting |
|
| 09.40 - 10.20 | 1-1 Advancing the brain penetrant NLRP3 inhibitor NT-0796 into the clinic for the treatment of Parkinson's disease
Alan Watt, NodThera |
| 10.20 - 11.00 | 1-2 DNA polymerase theta inhibition as a novel cancer therapy
Graeme Smith, Artios |
| 11.00 - 11.30 | Coffee break and exhibitors |
|
Session 2 Chair: Mike Hann, GSK |
|
| 11.30 - 12.30 | 2-1 SMR Award lecture and
presentation The UK Vaccine Taskforce. From inception to vaccination. Vaccine Taskforce leadership team members: Clive Dix, C4X Discovery Ian McCubbin, Cell and Gene Therapy Catapult / RoslinCT |
| 12.30 - 13.30 | Lunch break and exhibitors |
|
Session 3 Chair: David Hirst, MSD |
|
| 13.30 - 14.10 | 3-1 Invention of MK-0616 a Macrocyclic Peptide Oral PCSK9 Inhibitor Abbas Walji, MSD |
| 14.10 - 14.50 | 3-2 Discovery of GSK3358699, a Mononuclear Myeloid-Targeted pan-BET Bromodomain Inhibitor
Phil Humphreys, GSK |
| 14.50 - 15.20 | Coffee break and exhibitors
|
|
Session 4 Chair: Mike Hann, GSK |
|
| 15.20 - 16.00 | 4-1 Discovery of STC15, the First
Molecule Specifically Targeting an RNA Methyltransferase Enzyme to Enter Clinical Development
Beth Thomas, Storm Therapeutics |
| 16.00 - 16.40 | 4-2 NXP800: a first-in-class, orally available, clinical-stage, investigational activator of the integrated stress response for treatment of ARID1A-mutated, platinum-resistant ovarian cancer
Prof Paul Workman, Centre for Cancer Drug Discovery, The Institute of Cancer Research (ICR), Sutton, London SW7 3RP |
| 16.40 | Closing remarks and meeting ends Mike Hann, GSK |